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Abstract
Background: The benefits of live donor kidney transplantation must be balanced against the potential harm to the
donor. Well-designed prospective studies are needed to study the long-term consequences of kidney donation.
Methods: The “LOng-term follow-up after liVE kidney donation” (LOVE) study is a single center longitudinal cohort
study on long-term consequences after living kidney donation. We will study individuals who have donated a
kidney from 1981 through 2010 in the Erasmus University Medical Center in Rotterdam, The Netherlands. In this
time period, 1092 individuals donated a kidney and contact information is available for all individuals. Each
participating donor will be matched (1:4) to non-donors derived from the population-based cohort studies of the
Rotterdam Study and the Study of Health in Pomerania. Matching will be based on baseline age, gender, BMI,
ethnicity, kidney function, blood pressure, pre-existing co-morbidity, smoking, the use of alcohol and highest
education degree. Follow-up data is collected on kidney function, kidney-related comorbidity, mortality, quality of
life and psychological outcomes in all participants.
Discussion: This study will provide evidence on the long-term consequences of live kidney donation for the donor
compared to matched non-donors and evaluate the current donor eligibility criteria.
Trial registration: Dutch Trial Register NTR3795.
Keywords: Living donors, Nephrectomy, Kidney transplantation, Follow-up studies, Cohort studies
Background
Renal transplantation is the ultimate treatment for pa-
tients with end-stage renal disease (ESRD) [1]. The rise of
live donor kidney transplantation has helped to narrow
the gap between organ shortage and the number of ESRD
patients on the transplant waiting list [2]. The benefits of
live donor kidney transplantation, such as pre-emptive
transplantation, superior organ quality and increased graft
survival are well-known [1]. As a result live kidney dona-
tion has increased to one third of all kidney transplanta-
tions in the last decade [3]. In our transplant center over
fifty percent of the kidney transplantations are performed
with a kidney of a living donor. Live donor nephrectomy
is performed on healthy individuals who willingly undergo
major surgery for the benefit of someone else. Over the
years, the discomfort of the operation has been minima-
lized to minimal invasive procedures in many centers with
excellent quality of life [4–6].
The benefits for the recipient must be balanced against
the potential harm to the donor. Studies on short-term
follow-up show excellent results regarding kidney func-
tion, mortality and morbidity [7–10]. Reports have re-
cently been published on increased long-term risk of
ESRD [11–13] and increased risk of mortality following
live kidney donation [14]. Studies on follow-up of ten
years or more of live kidney donors demonstrate that the
morbidity and mortality increases with the duration of
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follow-up and subsequent aging. More importantly, these
long-term studies comparing donors with non-donors
have contradictory outcomes regarding kidney function,
incidence of hypertension, ESRD and mortality detriment
to donors. The main reason for these contradictory results
is the methodology of the different studies [14–22] which
jeopardizes the comparability of donors and non-donors.
Furthermore, the incidence of minor co-morbidities
among the general population is increasing and quickly
become the standard in the potential Western donor
population. This could potentially include an increase of
incident co-morbidities among previous donors. The oc-
currence of some of these co-morbidities takes years to
emerge and might be missed during a short-term follow-
up. In addition, the shortage of kidney donors has led to
an extension of the donor acceptance criteria in the re-
cent years, were donors with co-morbidities such as car-
diovascular disease, obesity and higher age are no longer
denied for donation [23, 24]. Thus emphasizing the need
for long-term follow-up of those who donated, including
live kidney donors who donated with pre-existing co-
morbidities.
To date most studies have merely focused on medical
outcomes, resulting in a paucity of research on long-
term psychological outcomes [25]. Current published
studies focus mainly on the level of quality of life shortly
after live kidney donation, which is high [5, 26–28].
Other outcomes, such as depression and anxiety, as well
as the potential positive influence of donation on mental
health, are often neglected. Therefore, an interesting
question is to which extent the donation has had a posi-
tive effect on the psychological well-being of the donor.
The aim of this study is to evaluate long-term conse-
quences after live kidney donation for the donor regard-
ing kidney function, the incidence of hypertension, the
incidence of diabetes mellitus, the incidence of fatal and
non-fatal cardiovascular events, survival, quality of life
and psychological well-being when compared to non-
donors, and in addition within the donor population.
Donors often do not make the decision to donate based
on balancing risks and benefits but rather based on emo-
tional or moral reasons. This makes it crucial to inform
donors in a standardized uniform fashion when obtain-
ing informed consent [29]. Determining the long-term
impact of living donation on physical and psychological
well-being is an essential part of evaluating the current
donor eligibility criteria and further developing and
expanding the live kidney donation program.
Methods
Participants and procedure - live kidney donors
The Netherlands has the highest number of live kidney
donor transplantations in Europe spread over eight kid-
ney transplant centers, with an annual living donation
rate of 31.0 per million population in 2013 [30]. Over
the years the Erasmus University Medical Center has de-
veloped the largest live kidney donation program of its
country with approximately 140 procedures per year and
is the referral center for other transplant centers in the
country. In 2014, a total of 397 live kidney donor trans-
plantations were performed in the Netherlands [31].
Thirty-five percent of these procedures were performed
at Erasmus University Medical Center. All donors who
donated a kidney from 1981 through 2010 at the depart-
ment of Surgery of the Erasmus University Medical Cen-
ter or who had their full medical work-up here prior to
donation, but donated in another transplant center be-
cause of their participation in the national kidney ex-
change transplant program will be eligible to be
included in this study. All donors were screened pre-
operatively by a nephrologist, transplant surgeon,
anesthesiologist, and social worker and underwent im-
aging by renal angiography, magnetic resonance imaging
or computerized tomography scan. Since 1981, data on
pre-donation characteristics such as prior medical his-
tory, medication use, BMI, as well as blood and urine
analysis regarding kidney function have been collected.
Furthermore, consecutive donors included in two ran-
domized controlled trials on surgical techniques between
2001–2004 and 2008–2010 [4, 32, 33] have completed
questionnaires on quality of life pre-donation and at set
times after the procedure, using the SF-36 questionnaire
and EuroQoL questionnaire. Donors are monitored an-
nually on their kidney function by blood- and urine ana-
lysis, blood pressure, weight and other current medical
issues at the department of Nephrology of the Erasmus
University Medical Center or another hospital, or by
their general practitioner. Up to 2011, this database
comprises 1092 live kidney donors. Approval of the
Medical Ethical Committee was obtained (MEC-2012-
519). Pre-donation characteristics on kidney function,
BMI, pre-existing co-morbidity and medication of all do-
nors will be updated in accordance with the hospital’s
electronic patient system. Mortality will be checked in
accordance with the Municipal registry. All donors who
are alive will be invited by post to visit the outpatient
clinic of one of three hospitals in different regions of the
Netherlands for an extensive follow-up appointment,
supplementary to their yearly check-up. During the
study-visit the donor and study investigators will sign
the consent form. During their study-visit, blood and
urine will be collected for analysis and donors will
undergo two interviews regarding quality of life and
their psychological well-being. Furthermore, an ultra-
sound of their remaining kidney will be performed to
measure the size. Participating donors will be reim-
bursed for their travel costs. Unexpected outcomes will
be reported to both the donor and the treating
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nephrologist, who will initiate subsequent examinations
and treatment if needed. The general practitioner and
any other treating specialist(s) will be notified if needed.
Non-responders will be contacted once again and non-
participants will be asked to fill out and return a ques-
tionnaire on their medical history and quality of life. In
addition, non-participants will be asked to give permis-
sion to request recent laboratory results on kidney func-
tion and new-onset co-morbidities from their medical
records, in order to analyze a potential selection bias. To
strengthen our results, we aim for a response of 70 per-
cent or higher. All private data are anonymized by allo-
cating a study number. The coordinating investigators
and the principal investigator are the only ones who
have access to the coding system. All data will be en-
tered into a database, which is managed by the coordin-
ating investigators. At the end of the study all data will
be analysed together with the trial statistician (DR).
Participants and procedure - non-donors
Non-donors will be selected from the Study of Health
in Pomerania (SHIP) [34, 35] and the Rotterdam Study
[36, 37], both population based cohort studies to cover
the whole age range of our donors.
SHIP is a population-based cohort study initiated in
1997 among inhabitants of West Pomerania in the
north-east of Germany. Two main objectives of this
study were first to assess prevalence and incidence of
common risk factors, subclinical disorders and clinical
diseases, and second to investigate the complex associa-
tions among these [34, 35]. Data on kidney function,
blood pressure, BMI, medication, incidence of cardiovas-
cular disease and diabetes, psychological well-being and
quality of life have prospectively been recorded [34].
SHIP comprises two cohorts aged 20–79 years. In our
matched study, the first cohort will be used due to the
longer follow-up (n = 4308). Multiple follow-up exami-
nations of this first cohort were conducted between
1997 and 2015.
The Rotterdam Study is a prospective cohort study
that started in 1990 in Ommoord, a neighborhood in
Rotterdam, the Netherlands. The study targets cardio-
vascular, endocrine, hepatic, neurological, ophthalmic,
psychiatric and respiratory diseases [36, 37]. As of 2008,
14,926 subjects aged 45 years or over were included.
Data such as hypertension, serum creatinine, serum
eGFR, cardiac events, mortality, diabetes, quality of life
and psychological well-being have prospectively been re-
corded [37]. The Rotterdam study comprises three dif-
ferent cohorts. We will use the second and the third
cohort to select non-donors (n = 6943), since these com-
prises more study parameters compared to the first co-
hort. Multiple follow-up examinations of these two
cohorts were conducted between 2000 and 2012. Given
the size of both studies, sufficient data on all study pa-
rameters will be available in our reference group.
Outcome measures
The primary outcome is kidney function in serum cre-
atinine and eGFR (calculated with the CKD-EPI formula)
[38]. Secondary outcomes are: diastolic and systolic
blood pressure as measured by data scope, incidence of
hypertension and incidence of diabetes, incidence of
fatal and non-fatal cardiovascular diseases, volume of
the remaining kidney in cm3 by ultrasound (measured
by experienced ultrasonographers), quality of life (mea-
sured by EuroQoL and SF-12, that can be extracted from
any SF-36 [39, 40]), survival, and psychological well-
being (for donors aged 45 years and higher with Hospital
Anxiety and Depression Scale (HADS) [41], Center for
Epidemiologic Studies Depression Scale (CESD) [42],
Pittsburgh Sleep Quality Index (PSQI) [43], and ques-
tionnaires on Happiness and Life Satisfaction, and for
donors aged 44 years and lower with the Beck Depres-
sion Inventory (BDI)) [44]. These outcomes will be com-
pared between groups, but also within the donor cohort.
Missing data and matching
Participants from the Rotterdam Study and SHIP will be
restricted from analysis if they would not qualify for live
kidney donation based on the following criteria: preva-
lent diabetes, an eGFR < 60 ml/min/1.73m2, and a BMI >
40 (kg/m2). To account for the fact that data for covari-
ates at baseline are not complete for all subjects, a mul-
tiple imputation approach will be utilized based on the
method of chained equations [45]. Using this procedure
10 complete data sets will be created, and for each of
the data sets the following steps will be performed: First,
donors and non-donors will be 1:4 matched using pro-
pensity score matching based on the baseline covariates:
age, gender, year of donation/inclusion, BMI, ethnicity,
kidney function, blood pressure, pre-existing co-
morbidity, glucose level, smoking, alcohol use and high-
est education degree. Exact matching will be required
for gender, ethnicity, existing co-morbidity, and smok-
ing. Progressive radius matching will be performed for
age, BMI, kidney function and blood pressure. Each
non-donor subject will be allowed to serve as a potential
match to more than one donor. If the available data in
the control group is insufficient, the target ratio of 1:4
donor:non-donor will be reduced accordingly.
Statistical analysis
All analyses will be performed for each of the completed
data sets and the results will be appropriately pooled.
For the medical outcomes a conditional linear or Cox
regression analysis will be chosen as appropriate for the
outcome. For the Cox regression analysis, the
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proportional hazards assumption will be tested with
Schoenfeld residuals. For the psychological outcomes
linear mixed-effects models will be used.
For donor subgroup analysis, parametric and non-
parametric tests will be chosen as appropriate for de-
scriptive comparisons, Cox regression analysis will be
chosen to investigate different outcomes, and mixed
models will be chosen for repeated variables, e.g. kidney
function and quality of life.
Discussion
Recently, studies have emerged that demonstrated un-
favourable outcomes after live kidney donation with re-
gard to the long-term risk of ESRD and increased risk of
mortality [13, 14]. Donors are a screened and selected
population of healthy individuals and therefore it is of
utmost importance to maximize both short-term and
long-term donor safety. However, high quality studies on
long-term outcome after live kidney donation are not
very common. Till date there are nine studies in which
long-term outcomes are compared between donors and
selected non-donors with a follow-up of ten or more
years. These studies demonstrate contradictory results
regarding the incidence of morbidity and mortality fol-
lowing donation [15–22, 46].
There are differences in the methodology of these
studies questioning the comparability of donors and the
selected non-donors. No other study has looked into
the long-term consequences of live kidney donation in
the Dutch health care system. The nine studies were
published between 1992 and 2015, with the number of
donors ranging from 30 to 2269 and the average
follow-up period ranging from 10.9 to 23.7 years. Also,
most studies report on a selection of their entire donor
cohort. We intend to include our consecutive cohort
from the conception of our live kidney donor program
with an average follow-up of ten years. Furthermore,
due to the follow-up study visits next to registry data,
we will have the current physical examination, labora-
tory results, and medical status. This will provide add-
itional information on potential donors at risk for
unfavourable outcomes. The previous studies derived
their non-donors from siblings of the donors [17],
background/general population [16, 21, 22], and
population-based cohort studies [15, 18, 19, 46]. Fur-
thermore, the matching of donors to non-donors was
performed based on different characteristics, e.g. age,
gender, BMI. Due to our extensive data collection of
donors and the prospective data collection of our com-
parison group we can strive for more comparability be-
tween donors and non-donors. We intend to match our
donors on all characteristics provided in previous stud-
ies and more for a better comparability of donors and
non-donors.
All these variations might explain the contradictory re-
sults. As donors are a highly selected healthy population,
comparison to the general population might lead to an
underestimation of long-term risks [16]. For this reason,
a study on long-term outcome, including baseline data
and a well-matched non-donor group, is the design of
choice. In the design of our study we tried to adhere to
suggestions of authors of these previous studies. The
current donor-cohort of our study forces us to use two
different population-based cohort studies to form our
non-donor group, as no single population-based study
incorporating representative individuals with a broad
enough age range provided the desired set of parame-
ters. Nevertheless, this design will facilitate in a one to
four proportion. Previous studies in our center in the
same living donor population have always resulted in a
high response [5, 6, 27, 47]. Although a selection bias
can never be precluded, analysis of the non-responding
group should provide us with an indication of whether
the sample is representative. Our study population in-
cludes elderly donors and donors with minor co-
morbidity. As there is currently little research on these
sub-groups, this study should clarify the ambiguities
concerning the long-term outcomes in these groups.
With this study we will try to overcome the limitations
of previous studies. We aim to assess the long-term con-
sequences of live kidney donation after a decade post-
donation. This study will compare donors with a
matched group of non-donors, regarding kidney func-
tion, kidney-related comorbidity, quality of life and psy-
chological outcomes.
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